{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:55:38Z","timestamp":1792547738477,"version":"4.5.0"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamaoncol.2021.4318","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T15:33:20Z","timestamp":1635435200000},"page":"130","source":"Crossref","is-referenced-by-count":61,"title":["Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1001","volume":"8","author":[{"given":"Emily R.","family":"Nadelmann","sequence":"first","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"crv210009r1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"crv210009r2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"crv210009r3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1158\/2326-6066.CIR-14-0217","article-title":"Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center.","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"crv210009r4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/1078155215572930","article-title":"Ipilimumab may increase the severity of cutaneous toxicity related to radiotherapy.","volume":"22","author":"Eryilmaz","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"crv210009r5","first-page":"183","article-title":"Treatment of skin reaction induced by nivolumab combined with radiotherapy in non\u2013small cell lung cancer: a case report.","volume":"33","author":"Zhao","year":"2018","journal-title":"Chin Med Sci J"},{"issue":"30","key":"crv210009r6","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events.","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"crv210009r7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"crv210009r8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"crv210009r9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"crv210009r10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2340\/00015555-2545","article-title":"Lichen planus in irradiated skin during nivolumab treatment.","volume":"97","author":"Komori","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"crv210009r11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/cup.2016.43.issue-4","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"10","key":"crv210009r12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy.","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"crv210009r13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/DAD.0000000000000587","article-title":"Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogrammed cell death-1 (anti-PD-1) therapy with or without ipilimumab.","volume":"39","author":"Chou","year":"2017","journal-title":"Am J Dermatopathol"},{"issue":"10","key":"crv210009r14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/cup.2017.44.issue-10","article-title":"PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation\u2014report of 4 cases.","volume":"44","author":"Chou","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"12","key":"crv210009r15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/cup.2017.44.issue-12","article-title":"Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy\u2014report of 2 patients.","volume":"44","author":"Tetzlaff","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"2","key":"crv210009r16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamaoncol.2018.4485","article-title":"Bilateral lower extremity skin eruptions in an HIV-positive man receiving pembrolizumab monotherapy for non\u2013small cell lung cancer.","volume":"5","author":"Boozalis","year":"2019","journal-title":"JAMA Oncol"},{"key":"crv210009r17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fonc.2018.00405","article-title":"Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet B phototherapy.","volume":"8","author":"Donaldson","year":"2018","journal-title":"Front Oncol"},{"key":"crv210009r18","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"crv210009r19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12885-019-5759-1","article-title":"Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.","volume":"19","author":"Cardis","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"crv210009r20","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1634\/theoncologist.2018-0531","article-title":"Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine.","volume":"24","author":"Fixsen","year":"2019","journal-title":"Oncologist"},{"key":"crv210009r21","article-title":"An atypical presentation of lichen planus\u2013like reaction from pembrolizumab.","volume":"2019","author":"Lee","year":"2019","journal-title":"Case Rep Dermatol Med"},{"issue":"9","key":"crv210009r22","doi-asserted-by":"crossref","DOI":"10.5070\/D3259045515","article-title":"Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.","volume":"25","author":"Mart\u00ednez-Dom\u00e9nech","year":"2019","journal-title":"Dermatol Online J"},{"issue":"4","key":"crv210009r23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000505353","article-title":"A case of nivolumab-induced cutaneous toxicity with multiple morphologies.","volume":"6","author":"Nguyen","year":"2020","journal-title":"Dermatopathology (Basel)"},{"issue":"4","key":"crv210009r24","first-page":"224","article-title":"Nivolumab-induced lichen planus pemphigoides.","volume":"103","author":"Strickley","year":"2019","journal-title":"Cutis"},{"issue":"3","key":"crv210009r25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1177\/1078155219866248","article-title":"Nivolumab-induced lichen planus.","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"crv210009r26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2019-0796","article-title":"Hypertrophic lichen planus with histological features of squamous cell carcinoma associated with immune checkpoint blockade therapy.","volume":"25","author":"Ameri","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"crv210009r27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/cup.v47.3","article-title":"Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.","volume":"47","author":"Coscarart","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"3","key":"crv210009r28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.annder.2019.07.008","article-title":"Bullous lichen planus and anti-programmed cell death-1 therapy: case report and literature review.","volume":"147","author":"de Lorenzi","year":"2020","journal-title":"Ann Dermatol Venereol"},{"issue":"10","key":"crv210009r29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/cup.v47.10","article-title":"Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma.","volume":"47","author":"Marques-Piubelli","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"1","key":"crv210009r30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"crv210009r31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"issue":"4","key":"crv210009r32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"issue":"8","key":"crv210009r33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.2016.43.issue-8","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"3","key":"crv210009r34","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1111\/ajd.2017.58.issue-3","article-title":"Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"3","key":"crv210009r35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ced.2017.42.issue-3","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"crv210009r36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid.","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"crv210009r37","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9602540","article-title":"Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management.","volume":"2018","author":"Lomax","year":"2018","journal-title":"J Skin Cancer"},{"issue":"11","key":"crv210009r38","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/ijd.2018.57.issue-11","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.","volume":"57","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"crv210009r39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"crv210009r40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/ programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature.","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"crv210009r41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer.","volume":"41","author":"Garje","year":"2018","journal-title":"J Immunother"},{"key":"crv210009r42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic pemphigus revealed by anti-programmed death-1 pembrolizumab therapy for cutaneous squamous cell carcinoma complicating hidradenitis suppurativa.","volume":"6","author":"Yatim","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"crv210009r43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/ijd.IJD_321_18","article-title":"Nivolumab-induced bullous pemphigoid managed without drug withdrawal.","volume":"65","author":"Munera-Campos","year":"2020","journal-title":"Indian J Dermatol"},{"issue":"3","key":"crv210009r44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jdcr.2020.01.008","article-title":"Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma.","volume":"6","author":"Virgen","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"5","key":"crv210009r45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CJI.0000000000000121","article-title":"Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non\u2013small cell lung cancer (NSCLC).","volume":"39","author":"Chia","year":"2016","journal-title":"J Immunother"},{"issue":"7","key":"crv210009r46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jdcr.2018.06.022","article-title":"Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin.","volume":"4","author":"Coleman","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"2","key":"crv210009r47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review.","volume":"10","author":"De Bock","year":"2018","journal-title":"Case Rep Dermatol"},{"issue":"10","key":"crv210009r48","article-title":"A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report.","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"crv210009r49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/1078155219877234","article-title":"Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.","volume":"26","author":"C Guven","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"crv210009r50","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients.","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"crv210009r51","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma.","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"10","key":"crv210009r52","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma.","volume":"30","author":"Kato","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"crv210009r53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/apm.12658","article-title":"Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.","volume":"125","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"APMIS"},{"issue":"2","key":"crv210009r54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma.","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"crv210009r55","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma.","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"11","key":"crv210009r56","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression.","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"crv210009r57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/ijd.IJD_46_17","article-title":"Anti-programmed cell death-1\u2013induced plaque and guttate psoriasis.","volume":"63","author":"Yamamoto","year":"2018","journal-title":"Indian J Dermatol"},{"issue":"4","key":"crv210009r58","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases.","volume":"4","author":"Phadke","year":"2016","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"6","key":"crv210009r59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis.","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"crv210009r60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jde.2017.44.issue-1","article-title":"Case of de novo psoriasis possibly triggered by nivolumab.","volume":"44","author":"Murata","year":"2017","journal-title":"J Dermatol"},{"issue":"11","key":"crv210009r61","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer.","volume":"55","author":"Law-Ping-Man","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"crv210009r62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma.","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"issue":"4","key":"crv210009r63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.2017.44.issue-4","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"1","key":"crv210009r64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000485910","article-title":"A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and\/or complementary immunomodulatory effects.","volume":"10","author":"Utsunomiya","year":"2018","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"crv210009r65","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1177\/1078155219830166","article-title":"Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.","volume":"25","author":"Dasanu","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"crv210009r66","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/1078155219890659","article-title":"Toxic epidermal necrolysis associated with pembrolizumab.","volume":"26","author":"Cai","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"crv210009r67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"crv210009r68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annder.2016.11.012","article-title":"[Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].","volume":"144","author":"Demirtas","year":"2017","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"crv210009r69","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2018.05.031","article-title":"Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient.","volume":"13","author":"Haratake","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"6","key":"crv210009r70","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"crv210009r71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","article-title":"Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.","volume":"4","author":"Griffin","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"1","key":"crv210009r72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/annonc\/mdx640","article-title":"Stevens-Johnson syndrome during nivolumab treatment of NSCLC.","volume":"29","author":"Salati","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"crv210009r73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1684\/ejd.2018.3295","article-title":"Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.","volume":"28","author":"Rouyer","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"6","key":"crv210009r74","doi-asserted-by":"crossref","DOI":"10.5070\/D3246040713","article-title":"Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.","volume":"24","author":"Shah","year":"2018","journal-title":"Dermatol Online J"},{"issue":"2","key":"crv210009r75","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000492172","article-title":"Atezolizumab-induced Stevens-Johnson syndrome in a patient with non\u2013small cell lung carcinoma.","volume":"10","author":"Chirasuthat","year":"2018","journal-title":"Case Rep Dermatol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2785675\/jamaoncology_nadelmann_2021_rv_210009_1642642433.33344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T16:17:16Z","timestamp":1642695436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2785675"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.4318","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}